Recro's IV meloxicam passes second Phase III test

Recro Pharma Inc. (NASDAQ:REPH) gained $1.54 (20%) to $9.30 after it said IV meloxicam (N1539) met the primary endpoint of a second Phase III study to treat acute postoperative pain. The therapy significantly reduced Summed Pain Intensity Difference scores over 24 hours (SPID24) vs. placebo in patients following abdominoplasty (p=0.0145).

The company plans to submit an NDA to FDA next summer for the cyclooxygenase-2 (COX-2) inhibitor, which was developed using NanoCrystal technology. ...